The World Diabetes Market, 2006-2025 A Key Pharmaceutical Market of the Future

Table of Contents

Chapter 1. Executive Summary

• 1.1 The Diabetes Market has High Potential
• 1.2 Aims, Scope and Format of the Report
• 1.3 Research Methodology

Chapter 2. Introduction to Diabetes

• 2.1 Introduction of Diabetes
  • 2.1.1 Type 1 Diabetes Description
    • 2.1.1.1 Causation of Type 1 Diabetes
      • 2.1.1.1.1 Auto-Immune Response
      • 2.1.1.1.2 Genetic Abnormalities
      • 2.1.1.1.3 Viral Infections
      • 2.1.1.1.4 Cow' s Milk
    • 2.1.1.2 Symptoms of Type 1 Diabetes
      • 2.1.1.2.1 Hypoglycemia
      • 2.1.1.2.2 Ketoacidosis
  • 2.1.2 Type 2 Diabetes Description
    • 2.1.2.1 Causes of Type 2 Diabetes
      • 2.1.2.1.1 Insulin Resistance
      • 2.1.2.1.2 Genetic Factors
    • 2.1.2.2 Symptoms of Type 2 Diabetes
    • 2.1.2.3 Gestational Diabetes
    • 2.1.2.4 Maturity-Onset Diabetes in Youth
    • 2.1.2.5 Secondary Diabetes
    • 2.1.2.6 Pre-Diabetes
• 2.2 Prevalence of Diabetes
  • 2.2.1. Diabetes Prevalence in the Seven Major Markets
  • 2.2.2 Diabetes Prevalence in Other Countries
  • 2.2.3 Mortality
  • 2.2.4 Diabetes Causes High Medication Expenditure
• 2.3 Diabetes Risk Factors
  • 2.3.1 Type 1 Diabetes risk Factors
  • 2.3.2 Type 2 Diabetes Risk Factors
    • 2.3.2.1 Obesity and Physical Inactivity
    • 2.3.2.2 Aged of 40 Years or Older
    • 2.3.2.3 Family History of Diabetes
    • 2.3.2.4 Diabetes During Pregnancy
    • 2.3.2.5 Ethnicity
    • 2.3.2.6 Low Birth Weight
    • 2.3.2.7 Hypertension
  • 2.3.3 Metabolic Syndrome and its Relationship to Diabetes
• 2.4 Diagnosing Diabetes
  • 2.4.1 Diagnostic Guidelines
  • 2.4.2 Diabetes Tests
    • 2.4.2.1 FPG (Fasting Plasma Glucose) Test
    • 2.4.2.2 OGTT (Oral Glucose Tolerance Test)
    • 2.4.2.3 Test for Glycosylated Haemoglobin
    • 2.4.2.4 Fructosamine
    • 2.4.2.5 Other Cautions for Diabetes Tests
• 2.5 Health Consequence of Diabetes
  • 2.5.1 Cardiovascular Disease
  • 2.5.2 Blindness
  • 2.5.3 Nervous System Disease and Amputations
  • 2.4.4 Dental Disease
  • 2.5.6 Complications in Pregnancy

Chapter 3. The Treatments for Diabetes

• 3.1 Introduction of Diabetes Treatments
  • 3.1.1 Introduction for Type 1 Diabetes Treatment
  • 3.1.2 Introduction for Type 2 Diabetes Treatments
• 3.2 Insulin Classification
• 3.3 Human Insulin
  • 3.3.1 Rapid-Acting Insulin
  • 3.3.2 Short-Acting Insulin
  • 3.3.3 Intermediate-Acting Insulin
  • 3.3.4 Long-Acting Insulin
  • 3.3.5 Ultra-Long-Acting Insulin
  • 3.3.6 Insulin Mixture
• 3.4 Animal Insulin
• 3.5 Oral anti-diabetes Drug (OADs) classification
  • 3.5.1 Alpha-Glucosidase Inhibitors (AGIs)
  • 3.5.2 Biguanides
  • 3.5.3 DDP-IV Inhibitors
  • 3.5.4 Meglitinides (Prandial Glucose Regulators: PGRs)
  • 3.5.5 Sulphonylureas
  • 3.5.6 Thiazolidiniones (TZDs)
• 3.6 Others Drugs
  • 3.6.1 Incretin Mimetic (GLP-1 agonist)
• 3.7 The Treatment of Type 2 Diabetes by Lifestyle Changes
  • 3.7.1 Diet and Weight Loss
  • 3.7.2 Exercise
  • 3.7.3 Monitoring blood glucose
  • 3.7.4 Daily Foot Care

Chapter 4. Global Diabetic Market Analysis

• 4.1 Overview of Diabetes Market by Drug Class
• 4.2 Current OAD Market Analysis
  • 4.2.1 Top OADs Analysis and Forecast
    • 4.2.1.1 Actos
    • 4.2.1.2 Avandia
• 4.3 Current Insulin Market
  • 4.3.1 Leading Insulins Analysis and Forecast
    • 4.3.1.1 Lantus Preforms Strongly in Insulin Market
    • 4.3.1.2 Humalog
    • 4.3.1.3 NovoRapid/NovoLog (insulin aspart)
    • 4.3.1.4 NovoMixChapter

Chapter 5. Diabetes Market Analysis by Countries

• 5.1 Overview of Global Market by Region
• 5.2 Diabetes Market Analysis in Seven Major Countries
  • 5.2.1 Diabetes Market Trends 2003 to 2006
  • 5.2.2 OAD Market Analysis
  • 5.2.3 OADs Sales Analysis and Sales Forecast in the Seven Major Markets
    • 5.2.3.1 Sales Analysis
    • 5.2.3.2 Sales Forecast for OADs Market
  • 5.2.4 Human Insulin Market Analysis in Seven Major Markets
    • 5.2.4.1 Current Insulin Market Analysis
    • 5.2.4.2 Sales Forecast for Insulin in the Seven Major Markets
    • 5.2.4.3 Conclusion
• 5.3 E7 Diabetes Market Analysis
  • 5.3.1 Current Market Analysis
  • 5.3.2 Analysis for the Four Leading Oral Antidiabetic Drugs in E7
  • 5.3.3 Sales Forecast in OADs Market in E7
  • 5.3.4 E7 Human Insulin Market Analysis
  • 5.3.5 Sales Forecast of E7 Insulin Market
  • 5.3.6 Conclusion

Chapter 6. Unmet Medical Needs for Diabetes Treatment and R&D

• 6.1 Unmet Medical Needs for Diabetes Treatments
• 6.2 New Development of Anti-Diabetic Drugs
  • 6.2.1 GLP-1 (Glucagon-Like Peptide-1) Inhibitors
  • 6.2.2 Future DDP-IV Iinhibitors
  • 6.2.3 SGLT (Sodium Glucose Co-Transporter Inhibitor)
  • 6.2.4 Glucokinase Activators
  • 6.2.5 Gluconeogesis Inhibitors
  • 6.2.6 PPAR ( Peroxisom Proliferators-Activated Receptors) Agonists
• 6.3 Insulin Delivery Technologies
  • 6.3.1 Insulin Jet Injections
  • 6.3.2 Insulin Pens
  • 6.3.3 Injection Aids
  • 6.3.4 Insulin Jet Injectors
  • 6.3.5 External Insulin Pumps
• 6.4 Introduction of New Delivery Technology
  • 6.4.1 Implantable Insulin Pumps
  • 6.4.2 Insulin Pills
  • 6.4.3 Transdermal Insulin
  • 6.4.4 Oral spray insulin
  • 6.4.5 Inhaled Insulin
  • 6.4.6 Insulin Patches
• 6.5 Other New Technologies for Type 1 Diabetes
  • 6.5.1 Organ transplantation
  • 6.5.2 Stem cell Technology
• 6.6 Blockbuster Anti-Diabetic Drugs
  • 6.6.1 Januvia (Sitagliptin)
  • 6.6.2 Galvus (Vildagliptin)
  • 6.6.3 Levemir (Insulin)
  • 6.6.4 Byetta (Exenatide)

Chapter 7. Key Players in the Global Diabetes Market

• 7.1 Eli Lilly
  • 7.1.1 Marked Diabetes Product Portfolio
    • 7.1.1.1 Actos (Pioglitazone)
    • 7.1.1.2 Byetta (Exenatide)
    • 7.1.1.3 Humalog (Insulin Lispro (rDNA Origin))
    • 7.1.1.4 Humalog Mix 75/25 & 50/50
    • 7.1.1.5 Humulin (Human Insulin (rDNA Original))
  • 7.1.2 R&D Pipeline Analysis
    • 7.1.2.1 Arxxant (Ruboxistaurin)
    • 7.1.2.2 AIR Insulin
  • 7.1.3 Strategic Analysis
• 7.2 GlaxoSmithKline
  • 7.2.1 Marketed Diabetes Product Portfolio
    • 7.2.1.1 Avandia (Rosiglitazone)
    • 7.2.1.2 Avandamet (Metformin/Rosiglitazone)
    • 7.2.1.3 Avandaryl (Rosiglitazone/ Glimepiride)
  • 7.2.2 R&D pipeline analysis
  • 7.2.3 Strategic Analysis
• 7.3 Novo Nordisk
  • 7.3.1 Marketed Diabetes Product Portfolio
    • 7.3.1.1 Actraphane HM (Human Mixtard/Novolin Mixtard/Actraphane)
    • 7.3.1.2 NovoMix (Insulin Aspart)
    • 7.3.1.3 NovoRapid/ NovoLog (Human Insulin Aspart)
    • 7.3.1.4 Levemir (Insulin Detemir)
    • 7.3.1.5 INS. Protaphane HM (Human Insulin)
    • 7.3.1.6 INS. Actrapid HM (Human Insulin)
    • 7.3.1.7 Novonorm/Prandlin (Repaglinide)
  • 7.3.2 R&D Pipeline Analysis
    • 7.3.2.1 Liraglutide (NN2211)
    • 7.3.2.2 AERx iDMS (NN1998)
    • 7.3.2.3 NovoNorm/Metformin Fixed Combo
    • 7.3.2.4 E1-INT
    • 7.3.2.5 GLP1-INT
    • 7.3.2.6 NN9101
  • 7.3.3 Strategic Analysis
• 7.4 Sanofi-Aventis
  • 7.4.1 Marked Diabetes Product Portfolio
    • 7.4.1.1 Apidra (Insulin Glulisine)
    • 7.4.1.2 Lantus (Insulin Glargine)
    • 7.4.1.3 Amaryl (Glimepiride)
    • 7.4.1.4 Daonil (Glibenclamide)& Diastabol (Miglitol)
  • 7.4.2 R&D Pipeline Analysis
    • 7.4.2.1 AVE0010
    • 7.4.2.2 AVE2268
    • 7.4.2.3 AVE0847
    • 7.4.2.4 AVE8134
    • 7.4.2.5 Others
  • 7.4.3 Strategic Analysis
• 7.5 Takeda
  • 7.5.1 Marketed diabetes product portfolio
    • 7.5.1.1 Actos (Pioglitazone Hydrochloride)
    • 7.5.1.2 Basen (Voglibose)
  • 7.5.2 R&D Pipeline Analysis
    • 7.5.2.1 Alogliptin (SYR-322)&AD-4833-536
    • 7.5.2.2 Others
  • 7.5.3 Strategic Analysis
• 7.6 Other Players in Diabetes Market
  • 7.6.1 Bayer
  • 7.6.2 Bistol-Mayers Squibb
  • 7.6.3 Pfizer
    • 7.6.3.1 Exubera(human insulin)
    • 7.6.3.2 R&D
    • 7.6.3.3 Strategies Analysis
  • 7.6.4 Merck KGaA
  • 7.6.5 Norvatis
  • 7.6.6 Servier

Chapter 8. SWOT Analysis for Global Diabetes Markets

• 8.1 Unmet Market Needs
• 8.2 SWOT Analysis
  • 8.2.1 Strengths
  • 8.2.2 Weaknesses
  • 8.2.3 Opportunities
  • 8.2.4 Threats
• 8.3 Key Drivers of Growth
• 8.4 Main Restraints of Growth

Chapter 9. Conclusion

• 9.1 Diabetes is a Severe Condition with High Prevalence
• 9.2 Existing Diabetes Treatment and the Promising New Drugs Delivery Technologies
  • 9.2.1 Existing Diabetes Treatment
  • 9.2.2 The Promising New Drugs Delivery Technologies
• 9.3 The Optimistic Future for Diabetes Market from 2007 to 2012
  • 9.3.1 Overview of diabetes drugs
    • 9.3.1.1 OADs
    • 9.3.1.2 Insulins
  • 9.3.2 Regional Breakdown of Revenues in the Anti-Diabetic Market
    • 9.3.2.1 Major Seven Countries Will Have Substantial Growth
    • 9.3.2.2 E7 Increase Rapidly on Antidiabetics Treatments
• 9.4 New Blockbusters Bring New Ways for Diabetes Treatments
• 9.5 The Key Drivers and Main Restraints for Diabetes Market
• 9.6 Outlook for the Future

List of Tables

• Table 2.1 Prevalence of Type 1 and Type 2 diabetes in the 7 major markets, 2004-2005
• Table 2.2 Top Ten Countries for Highest Estimated Cases of Diabetes, 2000 and 2030
• Table 2.3 World Mortality Caused by Diabetes, 2002, 2004 and 2006
• Table 2.4 Leading Causes of Death in the US 2004
• Table 2.5 World Estimates of the Costs of Diabetes Care in 2003 ($M)
• Table 2.6 Diabetes Expenditure in the Seven Major Countries ($M)
• Table 2.7 Diabetes Expenditure in E7 ($M)
• Table 2.8 Obese Population in Major Countries by Percentage (%)
• Table 3.1 Types of Human Insulin on the Market 2007
• Table 3.2 Oral Anti-diabetic Drugs 2007
• Table 4.1 World Antidiabetic Drugs Sales ($M) 2003-2006
• Table 4.2 Top Ten Antidiabetic Drugs Sales Performance ($M) 2003-2006
• Table 4.3 World Top OADs Sales Performance ($M) 2003-2006
• Table 5.1 World Diabetes Market by Countries 2003- 2006
• Table 5.2 Sales Forecast for OADS in Seven Major Markets ($M)
• Table 5.3 Insulin Sales Forecast in the Seven Major Countries ($M)
• Table 5.4 OADs Sales Trends by E7s ($M) 2006
• Table 5.5 OADs Distribution in E7s 2006
• Table 5.6 OADs Sales Performance in E7 ($M)
• Table 5.7 E7 OADS Sales Forecast ($M)
• Table 5.8 Insulin Distribution in E7s 2006
• Table 5.9 E7 Insulin Sales Performance ($M)
• Table 5.10 E7 Insulin Sales Forecast ($M)
• Table 5.11 Comparison of OADs and Insulin Sales in E7
• Table 6.1 Overview of GLP-1 Agonists in Development 2007
• Table 6.2 Overview of DDP-IV Inhibitors in Development
• Table 6.3 Overview of PPARz in Development
• Table 7.1 Eli Lilly Pipeline Development 2007
• Table 7.2 GSK Pipeline Developments 2007
• Table 7.3 Novo Nordisk Pipeline Developments 2007
• Table 7.4 Sanofi-Aventis Pipeline Developments
• Table 7.5 Takeda Pipeline Developments 2007
• Table 7.6 Pfizer Pipeline Developments 2007
• Table 8.1 SWOT Analysis for Diabetes Market
• Table 9.1 Diabetes Markets in Major Seven Markets and E7s ($M)

List of Charts

• Chart 2.1 US Diabetes Prevalence by Age 2005
• Chart 4.1 World Diabetes Market 2006
• Chart 4.2 Market Trends for Antidiabetic Drugs 2006
• Chart 4.3 World Top OADs Sales 2006
• Chart 4.4 World Market Trends of Top OADs 2006
• Chart 4.5 World Actos Sales 2006
• Chart 4.6 Sales Forecast of Actos ($M)
• Chart 4.7 World Avandia Sales 2006
• Chart 4.8 Sales Forecast for Avandia ($M)
• Chart 4.9 World Insulin Sales 2006
• Chart 4.10 Top Insulin Market Trends 2006
• Chart 4.11 Lantus World Sales 2006
• Chart 4.12 Sales Forecast of Lantus ($M)
• Chart 4.13 World Humalog Sales 2006
• Chart 4.14 Sales Forecast of Humalog ($M)
• Chart 4.15 World NovoRapid Sales 2006
• Chart 4.16 Sales Forecast of NovoRapid
• Chart 4.17 World NovoMix Sales 2006
• Chart 4.18 Sales Forecast of NovoMix ($M)
• Chart 5.1 Global Diabetes Market by Economic Geography 2006
• Chart 5.2 Diabetes Market Share in Seven Major Countries 2006
• Chart 5.3 OADs and Insulins Sales Performance in Seven Major Countries ($M) 2006
• Chart 5.4 OADs Market Share in Seven Major Countries 2006
• Chart 5.5 Top OADs Sales in Seven Major Markets ($M) 2006
• Chart 5.6 Top OADs Market Share in Seven Major Countries 2006
• Chart 5.7 OADs Sales Distribution in Seven Major Markets 2006
• Chart 5.8 Human Insulin Market in the Seven Major Countries 2006
• Chart 5.9 Insulin Sales Performance by Seven Major Markets ($M) 2006
• Chart 5.10 Top Insulin Market Share in the Seven Major Markets 2006
• Chart 5.11 Insulins Market Distribution by Seven Major Markets 2006 ($M)
• Chart 5.12 The Market Trends of OADs and Insulin in the E7 2006
• Chart 5.13 E7 OADs Market Share 2006
• Chart 5.14 E7s Leading OADs Performance by Sales Distribution 2006
• Chart 5.15 Leading OADs Sales Performance by E7s ($M) 2006
• Chart 5.16 E7s Insilin Market Share 2006
• Chart 5.17 E7 Insulin Sales Performance ($M)
• Chart 5.18 E7 Insulin Distribution 2006
• Chart 6.1 Sales Forecast of Januvia ($M)
• Chart 6.2 Sales Forecast of Galvus ($M)
• Chart 6.3 Levemir World Sales 2006
• Chart 6.4 Sales Forecast of Levemir ($M)
• Chart 6.5 Sales Forecast of Byetta ($M)

Organisations mentioned in this report

• Abbott
• Activa
• ADA (American Diabetes Association)
• Aimsco
• Ajinomoto
• Alantos
• Alkermes
• Alphapharm
• Altea Therapeutics
• Amcyte
• Amylin
• Andrx
• Animas
• Apothecary Products
• Astellas
• AstraZeneca
• Axordia
• Bayer
• Becton Dickinson
• Bentley
• Biocon
• Bioject Corp
• Boehringer Ingelheim
• Bristol Myers Squibb
• Can-Am Care
• CDC (US Centres for Disease Control and Prevention)
• ConjuChem
• CoreMed
• Dainippon Sumitomo
• Disetronic Medical Systems
• Dong Sung Pharmaceuticals
• Dr Reddy' s Laboratories
• Eli Lilly
• Emisphere Technologies
• Equidyne
• ESAD (European Association for the Study of Diabetes)
• ESI (Essential Science Indicators)
• Euromonitor
• Flamel Technologies
• Generex
• GlaxoSmithKline
• Glenmark Pharmaceutical
• Human Genome Science
• HypOview
• IDF (International Diabetes Federation)
• IMS
• Innovata
• Ivaz
• International Obesity Taskforce
• Kissei Pharmaceuticals
• Kos Pharmaceutical
• LifeScan
• Living Cell Technologies
• Lomonosov Moscow State University
• MannKind
• Massachusetts General Hospital
• MEDgenesis
• Medicool Inc.
• Medicore
• Medi-Ject Corp
• Medtronic
• Merck & Co.
• Merck KGaA
• Metabasis
• Microdose
• MiniMed
• Mylan
• NCEP
• Nektar Therapeutics
• Novartis
• Novo Nordisk
• OECD
• Owen Mumford
• Palco
• Perrigo
• Pfizer
• Phenomix
• Prosidion
• Ranbaxy
• Renovo
• Roche
• Sankyo Daiichi
• Sanofi-Aventis
• Serono
• Servier
• Takeda Pharmaceuticals
• Tanabe
• Teva
• Transition
• UltiMed
• University of Arahus
• University of Southern Denmark
• ViaCell
• Walgreens
• Wal-Mart
• Warner-Lambert Co.
• Watson
• Whittier Medical
• WHO
• Wockhardt
• Zesteem